Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37542
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | ABASIYANIK, Zuhal | - |
dc.contributor.author | Kahraman, T. | - |
dc.contributor.author | VELDKAMP, Renee | - |
dc.contributor.author | Ertekin, O. | - |
dc.contributor.author | Kalron, A. | - |
dc.contributor.author | Ozakbas, S. | - |
dc.contributor.author | FEYS, Peter | - |
dc.date.accessioned | 2022-06-20T09:09:12Z | - |
dc.date.available | 2022-06-20T09:09:12Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-06-09T11:27:29Z | - |
dc.identifier.citation | Multiple Sclerosis Journal, 28 (2) , p. 14 -15 | - |
dc.identifier.uri | http://hdl.handle.net/1942/37542 | - |
dc.description.abstract | Introduction: Accelerated early CGMV loss occurs in interferon-treated RMS patients. Methods: CGMV was quantified in randomized phase 3 (SUNBEAM-NCT02294058, RADIANCE-NCT02047734) trials comparing oral ozanimod 0.92 and 0.46mg/day with intramuscular interferon 30μg/ week and an ongoing, open-label extension trial (DAYBREAK-NCT02576717) of ozanimod 0.92mg/day in RMS. MRI was performed at months 6 (SUNBEAM), 12 (RADIANCE/SUNBEAM), and 24 (RADIANCE), then every 12 months (DAYBREAK). CGMV was analyzed through DAYBREAK month 36. Results: The rate of CGMV loss was greater (P<0.001) with inter-feron than ozanimod 0.92mg during SUNBEAM/RADIANCE: LS mean percentage change from baseline was-0.67% vs-0.02%, respectively, at month 6 and-1.04% vs-0.16% at month 12 in SUNBEAM, and-0.80% vs-0.13% at month 12 and-1.26% vs-0.53% at month 24 in RADIANCE. Switching from interferon to ozanimod reversed CGMV loss in year 1 of DAYBREAK. Thereafter, annualized rates of CGMV loss were similar among participants who switched from interferon and those continuously treated with ozanimod. Patients continuously treated with ozani-mod lost less CGMV in DAYBREAK relative to RADIANCE/ SUNBEAM baseline than patients initially treated with interferon. Conclusion: Switching from interferon to ozanimod reversed CGMV loss. Earlier treatment with ozanimod led to less CGMV loss over 4-5 years, supporting early ozanimod use. This abstract has been previously presented at AAN 2022 | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.title | Sustained attention during prolonged walking in persons with multiple sclerosis | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 15 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 14 | - |
dc.identifier.volume | 28 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | M | - |
local.publisher.place | 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.isi | WOS:000800913500036 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Abasiyanik, Z.; Veldkamp, R.; Feys, P.] Hasselt Univ, Fac Rehabil Sci, IREVAL Rehabil Res Ctr, Hasselt, Belgium. | - |
local.description.affiliation | [Abasiyanik, Z.] Dokuz Eylul Univ, Grad Sch Hlth Sci, Konak, Turkey. | - |
local.description.affiliation | [Abasiyanik, Z.; Kahraman, T.] Izmir Katip Celebi Univ, Dept Physiotherapy & Rehabil, Fac Hlth Sci, Izmir, Turkey. | - |
local.description.affiliation | [Veldkamp, R.; Feys, P.] UMSC, Hasselt Pelt, Kuala Lumpur, Malaysia. | - |
local.description.affiliation | [Ertekin, O.] Dokuz Eylul Univ, Fac Phys Therapy & Rehabil, Dept Neurol Physiotherapy Rehabil, Izmir, Turkey. | - |
local.description.affiliation | [Kalron, A.] Tel Aviv Univ, Sch Hlth Profess, Dept Phys Therapy, Sackler Fac Med, Tel Aviv, Israel. | - |
local.description.affiliation | [Ozakbas, S.] Dokuz Eylul Univ, Dept Neurol, Fac Med, Izmir, Turkey. | - |
local.uhasselt.international | yes | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | ABASIYANIK, Zuhal; Kahraman, T.; VELDKAMP, Renee; Ertekin, O.; Kalron, A.; Ozakbas, S. & FEYS, Peter (2022) Sustained attention during prolonged walking in persons with multiple sclerosis. In: Multiple Sclerosis Journal, 28 (2) , p. 14 -15. | - |
item.contributor | ABASIYANIK, Zuhal | - |
item.contributor | Kahraman, T. | - |
item.contributor | VELDKAMP, Renee | - |
item.contributor | Ertekin, O. | - |
item.contributor | Kalron, A. | - |
item.contributor | Ozakbas, S. | - |
item.contributor | FEYS, Peter | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Multiple Sclerosis Journal.pdf | Published version | 63.86 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.